Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
RESEARCH TOOLSreports
Holding ACAD?
Track your performance easily
ACAD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.55 - $32.59
Previous Close$16.33
Volume288.37K
Average Volume (3M)1.71M
Market Cap
$2.73B
Enterprise Value$2.18B
Total Cash (Recent Filing)$572.47M
Total Debt (Recent Filing)$47.19M
Price to Earnings (P/E)91.5
Beta1.02
Next Earnings
Oct 31, 2024EPS Estimate
$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding165,876,052
10 Day Avg. Volume921,939
30 Day Avg. Volume1,708,430
Standard Deviation0.15
R-Squared0.02
Alpha-0.00198
Financial Highlights & Ratios
Price to Book (P/B)5.25
Price to Sales (P/S)3.03
Price to Cash Flow (P/CF)27.00
P/FCF Ratio27.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit3.19
Enterprise Value/Ebitda43.24
Forecast
1Y Price Target
$26.93Price Target Upside63.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
ACADIA Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Earnings2Q24 results beat on the top and bottom lines, driven by Nuplazid upside.
International GrowthAcadia expects potential approval for Daybue in Canada and plans to submit filings in Europe and Japan, showing international growth prospects.
Sales GrowthNuplazid sales guidance increased to $590M-$610M (from $560M-$590M).
Bears Say
Investor SentimentShares remain under pressure due to negative sentiment from label expansion setbacks and challenging patient dynamics.
Revenue GuidanceLowered guidance for Daybue, a key investor focus, could trigger an initial hit to the stock.
Sales PerformanceDisappointing Daybue sales have led to reduced full-year revenue guidance.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.55 and its highest was $32.59 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Aug 06, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of $0.178 by $0.022.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.13.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 165,876,050 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.2 in its last earnings report, beating expectations of $0.178. Following the earnings report the stock price went down -19.523%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 697M.
---
ACADIA Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.93 (63.81% Upside)
$26.93 (63.81% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 33.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.12%
12-Months-Change
Fundamentals
Return on Equity
6.70%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q2 2024
0:00 / 0:00
---
ACAD Stock 12 Month Forecast
Average Price Target
$26.93
▲(63.81% Upside)
Technical Analysis
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
14/24 ratings generated profit
1 Year Average Return
+6.84%
assigned a buy rating last month
Copying Ritu Baral's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +6.84% per trade.
---